サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1511910

抗糖尿病薬の市場規模、シェア、動向分析レポート：薬剤クラス別、タイプ別、投与経路別、流通チャネル別、地域別、セグメント別予測、2024年～2030年

Antidiabetics Market Size, Share & Trends Analysis Report By Drug Class (GLP-1 Receptor Agonists, Insulin), By Type (Type 1, Type 2), By Route of Administration (Oral, Intravenous), By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 100 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.12円
抗糖尿病薬の市場規模、シェア、動向分析レポート：薬剤クラス別、タイプ別、投与経路別、流通チャネル別、地域別、セグメント別予測、2024年～2030年
出版日: 2024年06月19日
発行: Grand View Research
ページ情報: 英文 100 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

抗糖尿病薬市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の抗糖尿病薬市場規模は2023年から2030年にかけて12.23%のCAGRで拡大し、2030年には1,844億7,000万米ドルに達する見込みです。

糖尿病の有病率の増加がこの市場の主な促進要因です。不規則な食生活や肥満の増加も、対象疾患の罹患率を誘発することで製品需要を押し上げると予想されます。現在パイプラインにある製品の将来的な商業化と、アジア太平洋およびラテンアメリカの新興市場における大きな未開拓機会の存在が、今後の市場成長を促進すると予想されます。

インスリンは最も収益性の高いセグメントであり、その市場規模は2013年に200億米ドルを超えました。インスリンは、この市場で最も有利なセグメントの一つでもあります。より高い有効性を示す新製品のイントロダクションと、有利な政府のイニシアチブの存在が、市場の魅力を高める要因となっています。

抗糖尿病薬市場のレポートハイライト

  • 新たに承認されたジャヌビア、ネシーナ、オングリザなどのDPP-4阻害薬は、1日1回の投与レジメンと安全性プロファイルが評価され、急速に市場に浸透しました。
  • 北米は、2023年に市場の41.51%を占め、最も成熟した抗糖尿病薬市場であったインスリン製剤やその他の抗糖尿病薬の高い市場浸透率と高度な償還制度の存在が、同地域の市場成長を牽引すると予想されます。
  • アジア太平洋地域は、メーカーに有利な将来の成長機会をもたらすと期待されています。アンメットニーズが多く存在し、ヘルスケアインフラが急速に改善されていることが、同地域の市場成長を促進すると予想される要因のひとつです。また、現地メーカーによる安価な製品のイントロダクションも市場を牽引すると期待されています。
  • 抗糖尿病薬の主な市場プレイヤーには、AstraZeneca plc、Bayer AG、武田薬品工業、Eli Lilly and Company、Boehringer Ingelheim、Bristol-Myers Squibb Company、Merck &Co.Inc.、ジョンソン・エンド・ジョンソン・サービスInc.、ファイザー。
  • 市場は寡占的な性質を持っており、少数の企業が市場の70％以上を占めています。新製品開発を目的とした広範な研究開発投資と、政府との契約を通じた新興国市場への参入は、これらの企業が採用する主要な持続可能性戦略です。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 市場の変数、動向、範囲

  • 市場セグメンテーションと範囲
  • 市場系統の見通し
    • 親市場の見通し
    • 関連/補助市場見通し
  • 市場動向と展望
  • 市場力学
    • 糖尿病罹患率の上昇
    • 調査と技術の進歩
    • 意識の向上と早期介入
  • 市場抑制要因分析
    • 高い開発コスト
    • 副作用と安全性の懸念
  • 業界分析ツール
    • ポーターのファイブフォース分析
    • PESTEL分析
    • COVID-19の影響分析

第4章 薬剤クラス別ビジネス分析

  • 抗糖尿病薬市場：薬剤クラスの変動分析
  • インスリン
  • GLP-1受容体作動薬
  • DPP-4阻害剤
  • SGLT2阻害剤
  • DPP-4阻害剤
  • その他

第5章 糖尿病タイプ別ビジネス分析

  • 抗糖尿病薬市場：糖尿病タイプ別変動分析
  • タイプ1
  • タイプ2

第6章 投与経路別ビジネス分析

  • 抗糖尿病薬市場：投与経路の変動分析
  • 経口
  • 皮下
  • 静脈内

第7章 流通チャネル別ビジネス分析

  • 抗糖尿病薬市場：流通チャネル変動分析
  • オンライン薬局
  • 病院薬局
  • 小売薬局

第8章 地域別ビジネス分析

  • 地域別抗糖尿病薬市場シェア、2022年および2030年
  • 北米
    • SWOT分析
    • 北米の抗糖尿病薬市場、2018年-2030年
    • 米国
    • カナダ
  • 欧州
    • SWOT分析
    • 欧州の抗糖尿病薬市場、2018年-2030年
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • デンマーク
    • スウェーデン
    • ノルウェー
  • アジア太平洋地域
    • SWOT分析
    • アジア太平洋地域の抗糖尿病薬市場、2018年-2030年
    • 日本
    • 中国
    • インド
    • オーストラリア
    • タイ
    • 韓国
  • ラテンアメリカ
    • SWOT分析
    • ラテンアメリカの抗糖尿病薬市場、2018年-2030年
    • ブラジル
    • メキシコ
    • アルゼンチン
  • 中東・アフリカ
    • SWOT分析
    • 中東・アフリカ抗糖尿病薬市場、2018-2030年
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第9章 競合情勢

  • 企業分類
  • 戦略マッピング
  • 企業市場シェア分析、2022年
  • 企業プロファイル/上場企業
    • AstraZeneca plc
    • Bayer AG
    • Takeda Pharmaceutical Company Limited
    • Eli Lilly and Company
    • Boehringer Ingelheim
    • Bristol-Myers Squibb Company
    • Pfizer, Inc.
    • Johnson &Johnson Services Inc.
    • Merck &Co. Inc
    • Novartis AG
図表

List of Tables

  • Table 1 List of abbreviations
  • Table 2 Global antidiabetics market, by drug class, 2018 - 2030 (USD Million)
  • Table 3 Global antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 4 Global antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 5 Global antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 6 Global antidiabetics market, by region, 2018 - 2030 (USD Million)
  • Table 7 North America antidiabetics market, by country, 2018 - 2030 (USD Million)
  • Table 8 North America antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 9 North America antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 10 North America antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 11 North America antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 12 U.S. antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 13 U.S. antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 14 U.S. antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 15 U.S. antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 16 Canada antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 17 Canda antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 18 Canada antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 19 Canada antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 20 Europe antidiabetics market, by country, 2018 - 2030 (USD Million)
  • Table 21 Europe antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 22 Europe antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 23 Europe antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 24 Europe antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 25 UK antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 26 UK antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 27 UK antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 28 UK antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 29 Germany antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 30 Germany antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 31 Germany antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 32 Germany antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 33 France antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 34 France antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 35 France antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 36 France antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 37 Italy antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 38 Italy antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 39 Italy antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 40 Italy antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 41 Spain antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 42 Spain antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 43 Spain antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 44 Spain antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 45 Denmark antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 46 Denmark antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 47 Denmark antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 48 Denmark antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 49 Sweden antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 50 Sweden antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 51 Sweden antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 52 Sweden antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 53 Norway antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 54 Norway antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 55 Norway antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 56 Norway antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 57 Asia Pacific antidiabetics market, by country, 2018 - 2030 (USD Million)
  • Table 58 Asia Pacific antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 59 Asia Pacific antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 60 Asia Pacific antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 61 Asia Pacific antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 62 Japan antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 63 Japan antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 64 Japan antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 65 Japan antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 66 China antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 67 China antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 68 China antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 69 China antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 70 India antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 71 India antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 72 India antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 73 India antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 74 Australia antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 75 Australia antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 76 Australia antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 77 Australia antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 78 Thailand antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 79 Thailand antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 80 Thailand antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 81 Thailand antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 82 South Korea antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 83 South Korea antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 84 South Korea antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 85 South Korea antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 86 Latin America antidiabetics market, by country, 2018 - 2030 (USD Million)
  • Table 87 Latin America antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 88 Latin America antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 89 Latin America antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 90 Latin America antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 91 Brazil antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 92 Brazil antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 93 Brazil antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 94 Brazil antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 95 Mexico antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 96 Mexico antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 97 Mexico antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 98 Mexico antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 99 Argentina antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 100 Argentina antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 101 Argentina antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 102 Argentina antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 103 Middle East & Africa antidiabetics market, by country, 2018 - 2030 (USD Million)
  • Table 104 Middle East & Africa antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 105 Middle East & Africa antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 106 Middle East & Africa antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 107 Middle East & Africa antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 108 South Africa antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 109 South Africa antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 110 South Africa antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 111 South Africa antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 112 Saudi Arabia antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 113 Saudi Arabia antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 114 Saudi Arabia antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 115 Saudi Arabia antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 116 UAE antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 117 UAE antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 118 UAE antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 119 UAE antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 120 Kuwait antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 121 Kuwait antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 122 Kuwait antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 123 Kuwait antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value chain-based sizing & forecasting
  • Fig. 6 Market formulation & validation
  • Fig. 7 Antidiabetics market segmentation
  • Fig. 8 Market snapshot, 2022
  • Fig. 9 Market trends & outlook
  • Fig. 10 Market driver relevance analysis (current & future impact)
  • Fig. 11 Market restraint relevance analysis (current & future impact)
  • Fig. 12 SWOT analysis, by factor (political & legal, economic, and technological)
  • Fig. 13 Porter's Five forces analysis
  • Fig. 14 Market penetration & growth prospect mapping, 2022
  • Fig. 15 Global antidiabetics market: drug class movement analysis
  • Fig. 16 Global antidiabetics market, for Insulin, 2018 - 2030 (USD Million)
  • Fig. 17 Global antidiabetics market, for GLP-1 receptor agonists, 2018 - 2030 (USD Million)
  • Fig. 18 Global antidiabetics market, for DPP- 4 inhibitors, 2018 - 2030 (USD Million)
  • Fig. 19 Global antidiabetics market, for SGLT2 inhibitors, 2018 - 2030 (USD Million)
  • Fig. 20 Global antidiabetics market, for others, 2018 - 2030 (USD Million)
  • Fig. 21 Global antidiabetics market: diabetes type movement analysis
  • Fig. 22 Global antidiabetics market, for type 1, 2018 - 2030 (USD Million)
  • Fig. 23 Global antidiabetics market, for type 2, 2018 - 2030 (USD Million)
  • Fig. 24 Global antidiabetics market: route of administration movement analysis
  • Fig. 25 Global antidiabetics market, for oral, 2018 - 2030 (USD Million)
  • Fig. 26 Global antidiabetics market, for subcutaneous, 2018 - 2030 (USD Million)
  • Fig. 27 Global antidiabetics market, for intravenous, 2018 - 2030 (USD Million)
  • Fig. 28 Global antidiabetics market: distribution channel movement analysis
  • Fig. 29 Global antidiabetics market, for online pharmacies, 2018 - 2030 (USD Million)
  • Fig. 30 Global antidiabetics market, for hospital pharmacies, 2018 - 2030 (USD Million)
  • Fig. 31 Global antidiabetics market, retail pharmacies, 2018 - 2030 (USD Million)
  • Fig. 32 Regional marketplace: Key takeaways
  • Fig. 33 Regional outlook, 2022 & 2030
  • Fig. 34 Global antidiabetics market: region movement analysis
  • Fig. 35 North America antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 36 U.S. antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 37 Canada antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 38 Europe antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 39 Germany antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 40 UK antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 41 France antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 42 Italy antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 43 Spain antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 44 Denmark antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 45 Sweden antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 46 Norway antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 47 Asia Pacific antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 48 Japan antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 49 China antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 50 India antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 51 Australia antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 52 South Korea antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 53 Thailand antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 54 Latin America antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 55 Brazil antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 56 Mexico antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 57 Argentina antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 58 Middle East and Africa antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 59 South Africa antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 60 Saudi Arabia antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 61 UAE antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 62 Kuwait antidiabetics market, 2018 - 2030 (USD Million)
目次
Product Code: 978-1-68038-304-1

Antidiabetics Market Growth & Trends:

The global antidiabetics market size is expected to reach USD 184.47 billion by 2030, expanding at a CAGR of 12.23% from 2023 to 2030, according to a new report by Grand View Research, Inc. The growing prevalence of diabetes is the primary driver of this market. Growth in irregular dietary habits and obesity is also expected to boost product demand by triggering incidence rates of target diseases. Future commercialization of products currently in the pipeline and the presence of large untapped opportunities in the emerging Asia Pacific and Latin American markets is expected to fuel future market growth.

Insulin was the most revenue-generating segment and its market was valued at over USD 20.0 billion in 2013. Insulin is also one of the most lucrative segments of this market. The introduction of new products exhibiting higher efficacy coupled with the presence of favorable government initiatives are some factors attributing to its market attractiveness.

Antidiabetics Market Report Highlights:

  • The rapid uptake of newly approved DPP-4 inhibitors such as Januvia, Nesina, and Onglyza on account of their once-daily dosage regimens and safety profiles catalyzed the growth of this market.
  • North America was the most mature antidiabetics market in 2023 accounting for over 41.51% of the market High market penetration of insulin and other antidiabetics and the presence of sophisticated reimbursement framework are expected to drive regional market growth.
  • Asia Pacific is expected to present manufacturers with lucrative future growth opportunities. Large presence of unmet patient needs and rapidly improving healthcare infrastructure are some factors expected to drive market growth in the region. The market is also expected to be driven by the introduction of cheaper products made available by local manufacturers.
  • Some key market players of antidiabetics include AstraZeneca plc, Bayer AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim, Bristol-Myers Squibb Company, Merck & Co. Inc, Johnson & Johnson Services Inc. and Pfizer.
  • The market is oligopolistic in nature with few players accounting for over 70% of the market. Extensive R&D investments aimed at new product development and entering new markets via government contracts are the key sustainability strategies adopted by these organizations.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Segment Definitions
      • 1.1.1.1. Drug Class Segment
      • 1.1.1.2. Diabetes Type Segment
      • 1.1.1.3. Distribution Channel Segment
      • 1.1.1.4. Route of Administration Segment
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Objective
    • 1.4.1. Objective - 1
    • 1.4.2. Objective - 2
    • 1.4.3. Objective - 3
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information or Data Analysis:
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
  • 1.10. List of Secondary Sources
  • 1.11. List of Abbreviations

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Trends and Outlook
  • 3.4. Market Dynamics
    • 3.4.1. Rising Diabetes Prevalence
    • 3.4.2. Advancements in Research and Technology
    • 3.4.3. Increasing Awareness and Early Intervention
  • 3.5. Market Restraint Analysis
    • 3.5.1. High Development Costs
    • 3.5.2. Side Effects and Safety Concerns
  • 3.6. Industry Analysis Tools
    • 3.6.1. Porter's Five Forces Analysis
    • 3.6.2. PESTEL Analysis
    • 3.6.3. COVID-19 Impact Analysis

Chapter 4. Drug Class Business Analysis

  • 4.1. Antidiabetics Market: Drug Class Movement Analysis
  • 4.2. Insulin
    • 4.2.1. Insulin Market, 2018 - 2030 (USD Million)
      • 4.2.1.1. Insulin Market, By Type
      • 4.2.1.1.1. Long-acting insulin
      • 4.2.1.1.1.1. Long-acting insulin market, 2018 - 2030 (USD Million)
      • 4.2.1.1.2. Premix insulin
      • 4.2.1.1.2.1. Premix insulin market, 2018 - 2030 (USD Million)
      • 4.2.1.1.3. Fast-acting insulin
      • 4.2.1.1.3.1. Fast-acting insulin market, 2018 - 2030 (USD Million)
      • 4.2.1.1.4. Human insulin
      • 4.2.1.1.4.1. Human insulin market, 2018 - 2030 (USD Million)
  • 4.3. GLP-1 Receptor Agonists
    • 4.3.1. GLP-1 Receptor Agonists Market, 2018 - 2030 (USD Million)
  • 4.4. DPP- 4 Inhibitors
    • 4.4.1. DPP- 4 Inhibitors Market, 2018 - 2030 (USD Million)
  • 4.5. SGLT2 Inhibitors
    • 4.5.1. SGLT2 Inhibitors Market, 2018 - 2030 (USD Million)
  • 4.6. DPP-4 Inhibitors
    • 4.6.1. DPP- 4 Inhibitors Market, 2018 - 2030 (USD Million)
  • 4.7. Others
    • 4.7.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Diabetes Type Business Analysis

  • 5.1. Antidiabetics Market: Diabetes Type Class Movement Analysis
  • 5.2. Type 1
    • 5.2.1. Type 1 Market, 2018 - 2030 (USD Million)
  • 5.3. Type 2
    • 5.3.1. Type 2 Market, 2018 - 2030 (USD Million)

Chapter 6. Route of Administration Business Analysis

  • 6.1. Antidiabetics Market: Route of Administration Movement Analysis
  • 6.2. Oral
    • 6.2.1. Oral Market, 2018 - 2030 (USD Million)
  • 6.3. Subcutaneous
    • 6.3.1. Subcutaneous Market, 2018 - 2030 (USD Million)
  • 6.4. Intravenous
    • 6.4.1. Intravenous Market, 2018 - 2030 (USD Million)

Chapter 7. Distribution Channel Business Analysis

  • 7.1. Antidiabetics Market: Distribution Channel Movement Analysis
  • 7.2. Online Pharmacies
    • 7.2.1. Online Pharmacies Market, 2018 - 2030 (USD Million)
  • 7.3. Hospital Pharmacies
    • 7.3.1. Hospital Pharmacies, Market, 2018 - 2030 (USD Million)
  • 7.4. Retail Pharmacies
    • 7.4.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)

Chapter 8. Regional Business Analysis

  • 8.1. Antidiabetics Market Share By Region, 2022 & 2030
  • 8.2. North America
    • 8.2.1. SWOT Analysis
    • 8.2.2. North America Antidiabetics Market, 2018 - 2030 (USD Million)
    • 8.2.3. U.S.
      • 8.2.3.1. Key Country Dynamics
      • 8.2.3.2. Target Disease Prevalence
      • 8.2.3.3. Competitive Scenario
      • 8.2.3.4. Regulatory Framework
      • 8.2.3.5. U.S. Antidiabetics Market, 2018 - 2030 (USD Million)
    • 8.2.4. Canada
      • 8.2.4.1. Key Country Dynamics
      • 8.2.4.2. Target Disease Prevalence
      • 8.2.4.3. Competitive Scenario
      • 8.2.4.4. Regulatory Framework
      • 8.2.4.5. Canada Antidiabetics Market, 2018 - 2030 (USD Million)
  • 8.3. Europe
    • 8.3.1. SWOT Analysis
    • 8.3.2. Europe Antidiabetics Market, 2018 - 2030 (USD Million)
    • 8.3.3. UK
      • 8.3.3.1. Key Country Dynamics
      • 8.3.3.2. Target Disease Prevalence
      • 8.3.3.3. Competitive Scenario
      • 8.3.3.4. Regulatory Framework
      • 8.3.3.5. UK Antidiabetics Market, 2018 - 2030 (USD Million)
    • 8.3.4. Germany
      • 8.3.4.1. Key Country Dynamics
      • 8.3.4.2. Target Disease Prevalence
      • 8.3.4.3. Competitive Scenario
      • 8.3.4.4. Regulatory Framework
      • 8.3.4.5. Germany Antidiabetics Market, 2018 - 2030 (USD Million)
    • 8.3.5. France
      • 8.3.5.1. Key Country Dynamics
      • 8.3.5.2. Target Disease Prevalence
      • 8.3.5.3. Competitive Scenario
      • 8.3.5.4. Regulatory Framework
      • 8.3.5.5. France Antidiabetics Market, 2018 - 2030 (USD Million)
    • 8.3.6. Italy
      • 8.3.6.1. Key Country Dynamics
      • 8.3.6.2. Target Disease Prevalence
      • 8.3.6.3. Competitive Scenario
      • 8.3.6.4. Regulatory Framework
      • 8.3.6.5. Italy Antidiabetics Market, 2018 - 2030 (USD Million)
    • 8.3.7. Spain
      • 8.3.7.1. Key Country Dynamics
      • 8.3.7.2. Target Disease Prevalence
      • 8.3.7.3. Competitive Scenario
      • 8.3.7.4. Regulatory Framework
      • 8.3.7.5. Spain Antidiabetics Market, 2018 - 2030 (USD Million)
    • 8.3.8. Denmark
      • 8.3.8.1. Key Country Dynamics
      • 8.3.8.2. Target Disease Prevalence
      • 8.3.8.3. Competitive Scenario
      • 8.3.8.4. Regulatory Framework
      • 8.3.8.5. Denmark Antidiabetics Market, 2018 - 2030 (USD Million)
    • 8.3.9. Sweden
      • 8.3.9.1. Key Country Dynamics
      • 8.3.9.2. Target Disease Prevalence
      • 8.3.9.3. Competitive Scenario
      • 8.3.9.4. Regulatory Framework
      • 8.3.9.5. Sweden Antidiabetics Market, 2018 - 2030 (USD Million)
    • 8.3.10. Norway
      • 8.3.10.1. Key Country Dynamics
      • 8.3.10.2. Target Disease Prevalence
      • 8.3.10.3. Competitive Scenario
      • 8.3.10.4. Regulatory Framework
      • 8.3.10.5. Norway Antidiabetics Market, 2018 - 2030 (USD Million)
  • 8.4. Asia Pacific
    • 8.4.1. SWOT Analysis
    • 8.4.2. Asia Pacific Antidiabetics Market, 2018 - 2030 (USD Million)
    • 8.4.3. Japan
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Target Disease Prevalence
      • 8.4.3.3. Competitive Scenario
      • 8.4.3.4. Regulatory Framework
      • 8.4.3.5. Japan Antidiabetics Market, 2018 - 2030 (USD Million)
    • 8.4.4. China
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Target Disease Prevalence
      • 8.4.4.3. Competitive Scenario
      • 8.4.4.4. Regulatory Framework
      • 8.4.4.5. China Antidiabetics Market, 2018 - 2030 (USD Million)
    • 8.4.5. India
      • 8.4.5.1. Key Country Dynamics
      • 8.4.5.2. Target Disease Prevalence
      • 8.4.5.3. Competitive Scenario
      • 8.4.5.4. Regulatory Framework
      • 8.4.5.5. India Antidiabetics Market, 2018 - 2030 (USD Million)
    • 8.4.6. Australia
      • 8.4.6.1. Key Country Dynamics
      • 8.4.6.2. Target Disease Prevalence
      • 8.4.6.3. Competitive Scenario
      • 8.4.6.4. Regulatory Framework
      • 8.4.6.5. Australia Antidiabetics Market, 2018 - 2030 (USD Million)
    • 8.4.7. Thailand
      • 8.4.7.1. Key Country Dynamics
      • 8.4.7.2. Target Disease Prevalence
      • 8.4.7.3. Competitive Scenario
      • 8.4.7.4. Regulatory Framework
      • 8.4.7.5. Thailand Antidiabetics Market, 2018 - 2030 (USD Million)
    • 8.4.8. South Korea
      • 8.4.8.1. Key Country Dynamics
      • 8.4.8.2. Target Disease Prevalence
      • 8.4.8.3. Competitive Scenario
      • 8.4.8.4. Regulatory Framework
      • 8.4.8.5. South Korea Antidiabetics Market, 2018 - 2030 (USD Million)
  • 8.5. Latin America
    • 8.5.1. SWOT Analysis
    • 8.5.2. Latin America Antidiabetics Market, 2018 - 2030 (USD Million)
    • 8.5.3. Brazil
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Target Disease Prevalence
      • 8.5.3.3. Competitive Scenario
      • 8.5.3.4. Regulatory Framework
      • 8.5.3.5. Brazil Antidiabetics Market, 2018 - 2030 (USD Million)
    • 8.5.4. Mexico
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Target Disease Prevalence
      • 8.5.4.3. Competitive Scenario
      • 8.5.4.4. Regulatory Framework
      • 8.5.4.5. Mexico Antidiabetics Market, 2018 - 2030 (USD Million)
    • 8.5.5. Argentina
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Target Disease Prevalence
      • 8.5.5.3. Competitive Scenario
      • 8.5.5.4. Regulatory Framework
      • 8.5.5.5. Argentina Antidiabetics Market, 2018 - 2030 (USD Million)
  • 8.6. MEA
    • 8.6.1. SWOT Analysis
    • 8.6.2. MEA Antidiabetics Market, 2018 - 2030 (USD Million)
    • 8.6.3. South Africa
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Target Disease Prevalence
      • 8.6.3.3. Competitive Scenario
      • 8.6.3.4. Regulatory Framework
      • 8.6.3.5. South Africa Antidiabetics Market, 2018 - 2030 (USD Million)
    • 8.6.4. Saudi Arabia
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Target Disease Prevalence
      • 8.6.4.3. Competitive Scenario
      • 8.6.4.4. Regulatory Framework
      • 8.6.4.5. Saudi Arabia Antidiabetics Market, 2018 - 2030 (USD Million)
    • 8.6.5. UAE
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Target Disease Prevalence
      • 8.6.5.3. Competitive Scenario
      • 8.6.5.4. Regulatory Framework
      • 8.6.5.5. UAE Antidiabetics Market, 2018 - 2030 (USD Million)
    • 8.6.6. Kuwait
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Target Disease Prevalence
      • 8.6.6.3. Competitive Scenario
      • 8.6.6.4. Regulatory Framework
      • 8.6.6.5. Kuwait Antidiabetics Market, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Company Categorization
  • 9.2. Strategy Mapping
  • 9.3. Company Market Share Analysis, 2022
  • 9.4. Company Profiles/Listing
    • 9.4.1. AstraZeneca plc
      • 9.4.1.1. Overview
      • 9.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.1.3. Product Benchmarking
      • 9.4.1.4. Strategic Initiatives
    • 9.4.2. Bayer AG
      • 9.4.2.1. Overview
      • 9.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.2.3. Product Benchmarking
      • 9.4.2.4. Strategic Initiatives
    • 9.4.3. Takeda Pharmaceutical Company Limited
      • 9.4.3.1. Overview
      • 9.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.3.3. Product Benchmarking
      • 9.4.3.4. Strategic Initiatives
    • 9.4.4. Eli Lilly and Company
      • 9.4.4.1. Overview
      • 9.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.4.3. Product Benchmarking
      • 9.4.4.4. Strategic Initiatives
    • 9.4.5. Boehringer Ingelheim
      • 9.4.5.1. Overview
      • 9.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.5.3. Product Benchmarking
      • 9.4.5.4. Strategic Initiatives
    • 9.4.6. Bristol-Myers Squibb Company
      • 9.4.6.1. Overview
      • 9.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.6.3. Product Benchmarking
      • 9.4.6.4. Strategic Initiatives
    • 9.4.7. Pfizer, Inc.
      • 9.4.7.1. Overview
      • 9.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.7.3. Product Benchmarking
      • 9.4.7.4. Strategic Initiatives
    • 9.4.8. Johnson & Johnson Services Inc.
      • 9.4.8.1. Overview
      • 9.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.8.3. Product Benchmarking
      • 9.4.8.4. Strategic Initiatives
    • 9.4.9. Merck & Co. Inc
      • 9.4.9.1. Overview
      • 9.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.9.3. Product Benchmarking
      • 9.4.9.4. Strategic Initiatives
    • 9.4.10. Novartis AG
      • 9.4.10.1. Overview
      • 9.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.10.3. Product Benchmarking
      • 9.4.10.4. Strategic Initiatives